PCCTC Trial Is First to Use Standard Ra-223 Doses, Contemporary Pain Endpoints and PRO Collection Tools

Study published in Clinical Genitourinary Cancer details the first examining radium-223 in pain palliation using standard doses and contemporary pain end points radium-223, and demonstrated radium-223’s ability to palliate pain in a clinically meaningful manner in nearly one-half of enrolled patients.